Glenmark pharma launches generic version of Novartis' heart failure drug

Opens floodgates for more generic launches; 40 new brands expected

India’s Rs 20,000-crore cardiac drug market is in for a shake-up as generic launches of Novartis’ heart-failure drug Vymada begin. Mumbai-based Glenmark Pharmaceuticals on Monday announced the launch of their own brand of Sacubitril-valsartan tablets Sacu V, priced between Rs 19-35 per tablet.

Sheetal Sapale, president (marketing), AIOCD-AWACS said that at least 40 more brands are expected to be launched in this category, leading to a price erosion of at least 50 per cent.

Earlier in December, JB Pharma, which had acquired the Azmarda brand from Novartis AG, Switzerland for the India region for a consideration of Rs 246 crores